GlassScriptPhysician profile
Waleed Mahmoud
NPI 1366447062
$9,228.05
in general payments reported to CMS, 2019-2025
38 companies · $872 in 2025
The $872 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,272 · 2020: $838 · 2021: $1,748 · 2022: $1,445 · 2023: $1,607 · 2024: $1,445 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,022.13 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $959.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $899.01 | 2019-2025 | Jardiance |
| Pfizer INC. | $759.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $707.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $654.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $538.29 | 2019-2025 | Tymlos |
| Mylan Specialty L.P. | $535.49 | 2019-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $423.59 | 2021-2024 | Rexulti, Nuedexta |
| Lilly USA, LLC | $326.18 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $267.29 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.75 | 2019-2024 | Xifaxan |
| Dexcom, INC. | $214.08 | 2021-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $165.23 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $161.60 | 2019-2025 | Zoryve, Livalo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waleed Mahmoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.